Categories: Health

Ipsen – September 2025 – Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights
and shares composing the share capital

(in accordance with Article L.233-8 II of the French Commercial Code and
Article 223-16 of the General Regulation of the Autorité des Marchés Financiers)

Market: Euronext Paris
ISIN Code: FR 0010259150
LEI: 549300M6SGDPB4Z94P11

Date Total number of shares composing the share capital Total number of voting rights (1)
30 September 2025 83,814,526 Gross total* of voting rights: 132,053,087
Net total** of voting rights: 130,826,804

(1) Existence of a statutory clause imposing an obligation to declare threshold crossing complementary to the one relative to the legal thresholds (Article 10).

* Gross total = total number of voting rights attached to the total number of shares, including the number of shares which benefit of double voting rights and the number of treasury shares. The « Gross total » is used as a basis for the calculation of threshold crossings.

** Net total = total number of voting rights attached to the total number of shares – shares without voting rights.

GlobeNews Wire

Recent Posts

Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: Ocular Therapeutix, Inc. BEDFORD, Mass., Feb. 06, 2026…

16 minutes ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI,…

16 minutes ago

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing…

16 minutes ago

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies

AlUla, Saudi Arabia, Feb. 7, 2026 /PRNewswire/ -- The second edition of the AlUla Conference…

17 minutes ago

Roches fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint…

17 minutes ago

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

February 06, 2026 17:17 ET  | Source: Lexicon Pharmaceuticals, Inc. THE WOODLANDS, Texas, Feb. 06,…

17 minutes ago